Natco Pharma (NSE:NATCOPHARM) Margin of Safety % (DCF Earnings Based): 39.83% (As of Jun. 30, 2026)


NSE:NATCOPHARM Natco Pharma Ltd NSE:NATCOPHARM
89 GF Score
Price ₹919.50
GF Value ₹941.93
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Natco Pharma Margin of Safety % (DCF Earnings Based)?

Natco Pharma NSE:NATCOPHARM +1.75% 89 Margin of Safety % (DCF Earnings Based) is 39.83% as of Jun. 30, 2026. GuruFocus rates NSE:NATCOPHARM with a GF Score™ of 89/100 and a GF Value™ of ₹941.93 (Fairly Valued). The stock has 2 warning signs investors should review.

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

As of today (2026-06-30), Natco Pharma's Predictability Rank is 2-Stars. Natco Pharma's intrinsic value calculated from the Discounted Earnings model is ₹1528.15 and current share price is ₹919.50. Consequently,

Natco Pharma's Margin of Safety % (DCF Earnings Based) using Discounted Earnings model is 39.83%.

NSE:NATCOPHARM vs ZTS, UTHR: Margin of Safety % (DCF Earnings Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Natco Pharma's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Natco Pharma Margin of Safety % (DCF Earnings Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Natco Pharma's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Natco Pharma's Margin of Safety % (DCF Earnings Based) falls into.


NSE:NATCOPHARM
89GF Score
Natco Pharma Ltd NSE:NATCOPHARM
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Natco Pharma Margin of Safety % (DCF Earnings Based) Calculation

Natco Pharma's Margin of Safety % (DCF Earnings Based) for today is calculated as

Margin of Safety % (DCF Earnings Based)=(Intrinsic Value: DCF (Earnings Based)-Current Price)/Intrinsic Value: DCF (Earnings Based)
=(1528.15-919.50)/1528.15
=39.83 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The intrinsic value is calculated from the Discounted Earnings model with default parameters. The calculation method is the same as Discounted Cash Flow model except earnings are used in the calculation instead of free cash flow.

What does a Margin of Safety % (DCF Earnings Based) of 39.83% mean?
Natco Pharma (NSE:NATCOPHARM) has a Margin of Safety % (DCF Earnings Based) of 39.83% as of Jun. 30, 2026. Margin of Safety % (DCF Earnings Based) is the percent difference between the current price and the intrinsic DCF Earnings price. View historical data on Natco Pharma.
Is Natco Pharma's Margin of Safety % (DCF Earnings Based) too high?
Natco Pharma's current Margin of Safety % (DCF Earnings Based) is 39.83%. Overall, Natco Pharma has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Natco Pharma's Margin of Safety % (DCF Earnings Based) compare to ZTS and UTHR?
Natco Pharma's Margin of Safety % (DCF Earnings Based) of 39.83% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Margin of Safety % (DCF Earnings Based) for a Drug Manufacturers company?
A good Margin of Safety % (DCF Earnings Based) depends on the Drug Manufacturers industry context. However, Margin of Safety % (DCF Earnings Based) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Margin of Safety % (DCF Earnings Based) mean?
A high Margin of Safety % (DCF Earnings Based) can signal that a stock is expensive relative to its fundamentals. Margin of Safety % (DCF Earnings Based) is the percent difference between the current price and the intrinsic DCF Earnings price. View historical data on Natco Pharma. Natco Pharma's current Margin of Safety % (DCF Earnings Based) is 39.83%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Natco Pharma stock overvalued right now?
Based on GuruFocus' analysis, Natco Pharma (NSE:NATCOPHARM) is currently considered Fairly Valued. The stock's GF Value™ is ₹941.93, compared to a current price of ₹919.50 — trading 2.4% below its estimated fair value. The current Margin of Safety % (DCF Earnings Based) is 39.83%. Natco Pharma's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Margin of Safety % (DCF Earnings Based) calculated?
Margin of Safety % (DCF Earnings Based) is calculated from a company's financial statements. For Natco Pharma (NSE:NATCOPHARM), the current Margin of Safety % (DCF Earnings Based) is 39.83% as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Natco Pharma (NSE:NATCOPHARM) Overvalued in 2026?

Based on GuruFocus' analysis, Natco Pharma stock appears to be undervalued. The current stock price of ₹919.50 is trading 2.4% below its estimated GF Value™ of ₹941.93. GuruFocus considers Natco Pharma to be Fairly Valued.

Key valuation signals for NSE:NATCOPHARM:

  • Margin of Safety % (DCF Earnings Based): 39.83%
  • GF Value™: ₹941.93 vs. price of ₹919.50 (2.4% below fair value)
  • GF Score™: 89/100 with 2 warning signs

No single metric tells the full story. See the NSE:NATCOPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Natco Pharma Business Description

Other Exchanges 524816:India
Address Road No. 2, NATCO House, Banjara Hills, Hyderabad, TG, IND, 500034
Natco Pharma Ltd is a drug manufacturing company. Natco aims to make specialty medicines accessible to all by manufacturing niche pharmaceutical products backed by its research and development capabilities. While the vast majority of the company's revenue is generated in India, the company looks internationally for growth opportunities. The company maintains a presence in Oncology and Hepatology treatment areas. Natco's active pharmaceutical ingredient segment APIs forms a core part of the company's business. The company operates in two different business segments: pharmaceuticals and agrochemicals. It derives maximum revenue from Pharmaceuticals Segment.
89GF Score

Get the complete analysis for NSE:NATCOPHARM

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹919.50
Price
₹941.93
GF Value